Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Apr 26, 2024 9:49am
199 Views
Post# 36009108

Algorithms back in control

Algorithms back in control

We had a nice run over the last 6 months with the share price going from $1 to $2.56. We had lits of material news released during this time frame. We dosed our first patient for the AKI phase 2 trial and announced another trial to commence in the summer with our repurpised drug.

We now return to a silent period as we continue to dose patients across 6 Turkish locations and soon to commence in 3 Canadian sites.

We now sit and wait as the trials commence and dsta collected. 


The lack of buying has settled in as the big boys wait for data to signal positive results, the downside is that this lack data provides a very quiet period and breeds ideal environment for the Algorithms to take back control and manipulate the stock based on absolutely nothing. It is hard to watch the share price eroded daily by these banksters or should I say gangsters.

We are again beliw $100M usd market cap which in itself is ridiculous when you look at the science and compare Arch to similar staged companies. We should be well above $10 at this stage but our time will come, as they say "Patience is a virtue"

Good luck to all the shareholders who are long!

<< Previous
Bullboard Posts
Next >>